Abrus Precatorius Seed Aconitum Napellus Aethusa C

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Complex (100 Botanical/Natural Ingredients): Insufficient Data for Drug Repurposing Evaluation

One-Sentence Summary

This entry is a multi-ingredient homeopathic complex comprising approximately 100 botanical, mineral, and biological substances — including ingredients such as Aconitum napellus, Atropa belladonna, Arsenic trioxide, Matricaria chamomilla, and Sulfur, among others. No original approved indication, no TxGNN predicted indication, and no regulatory approval record could be identified for this combination product. As a result, no repurposing evaluation can be conducted at this stage; this case requires reclassification before proceeding.

Quick Overview

Item	Content
Original Indication	Not established — no regulatory approval found
Predicted New Indication	None — TxGNN returned no predictions for this entry
TxGNN Prediction Score	N/A
Evidence Level	Below L5 (no model output, no studies)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Is Available

This entry does not represent a single molecular drug entity. The inn field contains a semicolon-delimited list of approximately 100 distinct botanical extracts, minerals, and biological substances. This pattern is characteristic of homeopathic combination products, where each ingredient is typically used at highly diluted (potentised) concentrations.

The TxGNN knowledge graph model is designed to evaluate single active pharmaceutical ingredients (APIs) against a structured disease ontology. A compound entry of this format cannot be meaningfully mapped to a single DrugBank node or pharmacological mechanism, which explains why:

No DrugBank ID was resolved (drugbank_id: null)
No predicted indications were generated (predicted_indications: [])
No MOA data is available

Several individual components in this list do have known pharmacological activity when used as isolated compounds — most notably Arsenic trioxide (a licensed antineoplastic agent for acute promyelocytic leukemia) and Caffeine — but evaluating the combination as a whole is not feasible within the current pipeline framework.

Conclusion and Next Steps

Decision: Hold

Rationale: This entry cannot be evaluated as a drug repurposing candidate in its current form. It is a multi-ingredient homeopathic complex, not a single API, and TxGNN produced no predictions. There is no original indication, no regulatory history, and no safety data on file.

To proceed, the following is needed:

Reclassification: Determine whether this product is intended as a single registered homeopathic product. If so, identify the product’s registered brand name and official approved indication (if any) and re-submit with a single representative ingredient or the full product name.
Target API selection: If the intent is to evaluate a specific ingredient within this list (e.g., Arsenic trioxide), that ingredient should be extracted and submitted as a separate standalone evaluation case.
Regulatory source verification: Confirm whether this combination product has any registration record under a specific national pharmacopoeia (e.g., HPUS — Homeopathic Pharmacopoeia of the United States) or licensed homeopathic registration number.
Data pipeline review: The candidate_id value is TW-UNKNOWN-multi, suggesting this record may have been generated by an upstream mapping error. Review the source data ingestion step to prevent multi-ingredient strings from being treated as single drug candidates.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.